Seen in the press: Nemera’s article featured in January ‘Ophthalmic Drug delivery’January 14, 2019
“Ophthalmic Drug Delivery” magazine features Nemera’s article about the importance of user studies to understand what patients need.
The recently published “Ophthalmic Drug Delivery” magazine includes an article from Nemera: “User testing: critical for truly understanding patient needs”.
In this article, Fanny Sellier, Global Category Manager, Ophthalmic Products, Nemera, presents three comparative user studies between Nemera’s Novelia® preservative-free, multidose eyedropper and similar products from competitors, highlighting the need for user studies in addition to standard in vitro tests when assessing the quality of an ophthalmic drug delivery device.
Eyedropper performance is mainly evaluated by in vitro tests, such as the dose variability against shelf life, the sterility of the content and the delivered drop.
Despite these important in vitro tests, the usability aspects of the drug delivery system are not fully considered. Therefore, also conducting a user test evaluation is key because, even if it is successful according to the in vitro tests, an eyedropper may not necessarily be appreciated by patients due to poor usability. Consequently, a device with good in vitro test performance could be clinically inefficient.
The article reports on three user tests that have been conducted to evaluate the level of difference in terms of usability characteristics and user preferences for different preservative-free multidose systems.
The full article:
The full issue of the magazine:
Nemera is a world leader in the design, development and manufacturing of drug delivery devices for the pharmaceutical, biotechnology & generics industries.
Nemera always puts patients first, providing the most comprehensive range of devices in the industry, including off-the-shelf innovative systems, customized design development and contract manufacturing.